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ABSTRACT
Background. Previous studies have shown that, overall,
quality of life (QoL) decreases within the first 3–6 months
after cytoreductive surgery with hyperthermic intraperi-
toneal chemotherapy (CRS ? HIPEC), returning to
baseline levels by 6–12 months. This systematic review
aims to evaluate the factors affecting QoL after CRS ?
HIPEC within 12 months of surgery.
Methods. Electronic databases were investigated search-
ing for articles reporting QoL with validated questionnaires
up to September 2019. Risk of bias was assessed with the
methodological index for non-randomized studies tool. The
primary outcomes were short-term (\ 6 months after sur-
gery) and medium-term (6–12 months after surgery)
determinants of QoL after CRS ? HIPEC. Secondary
outcomes were QoL and reported symptoms over time.
Results. We included 14 studies that used 12 different
questionnaires. The reported data were collected prospec-
tively or retrospectively for 1556 patients (dropout\ 50%
in four studies). Overall, studies showed diminished QoL
within 3 months after surgery and a recovery to baseline or
greater by 12 months. QoL was negatively influenced by
higher age, female sex, prolonged operation time, extensive
disease, residual disease, adjuvant chemotherapy, compli-
cations, stoma placement, and recurrent disease. QoL
results were comparable between studies, with dropout
rates above and below 50%.
Conclusions. QoL returns to baseline levels within
12 months after CRS ? HIPEC provided the disease does
not recur, and this recovery process is influenced by several
factors.
Peritoneal metastases are present in advanced stages of
several abdominal tumors. If left untreated, they are asso-
ciated with poor prognosis, high morbidity, and reduced
quality of life (QoL).1–4 Peritoneal metastasis was once
considered incurable and suitable for only palliative treat-
ment.5–7 However, in carefully selected patients with
limited and resectable disease and who have no distant
metastases, research has shown that aggressive cytoreduc-
tive surgery (CRS) with hyperthermic intraperitoneal
chemotherapy (HIPEC) may be considered a curative
treatment option.8 In this extensive surgical procedure, all
macroscopic disease is removed from the abdominal cav-
ity, which is then perfused with heated chemotherapy
agents.9–11 Since the introduction of the CRS ? HIPEC
approach, multiple studies have shown improved prognosis
in appropriately selected patients with peritoneal metastasis
from various tumors. Today, CRS ? HIPEC is even
regarded as the standard of care for patients with peritoneal
metastasis of colorectal origin or in those with pseu-
domyxoma peritonei.5,12,13
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Despite the undoubted success of CRS ? HIPEC, the
approach remains a high-risk treatment with a mortality of
up to 8% and a morbidity of 23–66%, even in experienced
centers.9,14–19 Clinicians and patients must therefore seri-
ously weigh the potential survival benefits against the
substantial risk of treatment-related morbidity, mortality,
and a potentially diminished QoL and functional status.
Supporting this latter consideration, two systematic
reviews were recently published in which it was suggested
that patients who underwent CRS ? HIPEC experienced a
decrease in QoL, although this eventually returned to
baseline levels within 12 months of surgery.20,21 However,
both reviews relied on limited literature searches, and only
one reported a range of QoL domains.21 Furthermore,
neither review gave sufficient consideration to the deter-
minants of QoL after CRS ? HIPEC, such as stoma
placement,22 disease recurrence,22 and dropout rates. Note
that dropout rates can be highly selective and lead to the
most ill patients in a cohort being underrepresented. In
turn, this indicates the need for a further review of the
factors affecting change in QoL after CRS ? HIPEC in
patients with peritoneal metastasis.
The objective of this systematic review is to identify the
factors affecting QoL after CRS ? HIPEC in patients with
peritoneal metastasis over both the short-term (within
6 months of surgery) and the medium-term (6–12 months
after surgery).
MATERIALS AND METHODS
We conducted a systematic review and reported the
results according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) and the
Meta-analysis of Observational Studies in Epidemiology
(MOOSE) guidelines.23,24
Literature Search Strategy
The search strategy was developed in collaboration with
an experienced medical research librarian, and a full
description of the strategy can be found in Supplementary
Table 1. The systematic literature search was conducted in
October 2018 and updated in September 2019, using the
databases of PubMed, Embase, Cochrane library (trials),
and Web of Science. We aimed to identify prospective and
retrospective observational studies and randomized clinical
trials (RCTs) that met predefined eligibility criteria. The
Medical Subject Headings (MeSH) term ‘‘Quality of Life’’
and different terms for ‘‘HIPEC’’ were used. Only original
peer-reviewed research was included. No further restric-
tions were placed on the study design, language, or study
date. Finally, the references of included articles and related
review articles were manually screened to identify addi-
tional relevant studies.
Eligibility Criteria
Studies were included for review based on the following
eligibility criteria: (1) patients were treated with CRS ?
HIPEC, (2) reported QoL data were obtained by validated
questionnaires, (3) patients with colorectal peritoneal
metastasis were included, (4) data collection was
prospective, and (5) research was original and peer-re-
viewed. To guarantee that the publications were understood
at an academic level, the articles were required to be
written in English, Dutch, German, or Spanish. We
excluded any studies in which patients were retreated with
HIPEC or another intraperitoneal chemotherapy (e.g.,
postoperative intraperitoneal chemotherapy). Studies
reporting data only about patients with pseudomyxoma
peritonei or a primary malignancy of the appendix or
stomach were also excluded because of the different
prognosis compared with other CRS ? HIPEC indications.
Finally, studies with a cross-sectional design were exclu-
ded because one measurement point is insufficient to
measure the change in QoL.
Study Selection
Titles and abstracts were independently reviewed for
eligibility according to predefined criteria by two authors
(M.L. and J.H.). The reviewers were not blinded to publi-
cation date, journal, or authors. The full texts of potentially
eligible articles were retrieved and assessed for inclusion
independently by each author. Disagreement about study
inclusion was resolved by consensus or by discussion with
a third author (B.L.).
Data Extraction and Quality Assessment
Data extraction for predetermined items was performed
independently by two authors (M.L. and J.H.). The fol-
lowing data were extracted: first author, publication year,
country of origin, study years, study design, number of
patients, inclusion and exclusion criteria, age, sex, tumor
origin, morbidity and mortality related to CRS ? HIPEC,
QoL instruments used, measurement points, questionnaire
response rate, and mean overall and subscale QoL scores
(e.g., physical health, social health, emotional health,
functional health, and cognitive health). If data were not
reported, items were recorded as ‘‘NR’’ (not reported).
To evaluate the quality of the included articles, two
reviewers (M.L. and J.H.) independently conducted a risk
of bias analysis using the methodological index for non-
randomized studies (MINORS) for individual studies.25 In
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the event of disagreement, consensus was reached through
discussion or by consulting a third author (B.L.). The
MINORS criteria were specifically developed for use with
studies that have a surgical intervention. Each item can be
scored as 0 (not reported), 1 (reported but inadequate), or 2
(adequately reported), resulting in global ideal scores of 16
for noncomparative studies and 24 for comparative studies.
Although the tool gives an indication of the quality of
studies in different domains, it has no defined cut-off scores
for what constitutes high or low quality.
The interobserver reliability of the risk of bias assess-
ment was calculated using the intraclass correlation
coefficient (ICC). The ICC for interobserver reliability was
interpreted according to the definition of Landis and
Koch26 as follows: poor if\ 0.00, slight if 0.00–0.20, fair
if 0.21–0.40, moderate if 0.41–0.60, substantial if
0.61–0.80, and almost perfect if 0.81–1.00.
Outcomes
The primary outcomes were the short- (\ 6 months) and
medium-term (6–12 months) factors affecting QoL in
patients with peritoneal metastasis after CRS ? HIPEC.
The secondary outcome was the QoL after CRS ? HIPEC
in various domains after CRS ? HIPEC, including overall
health, physical health, emotional health, social health,




A total of 1759 potentially relevant records were iden-
tified from four databases (Fig. 1). After removing
duplicates, titles and abstracts of the remaining 869 records
were screened. This resulted in 31 full-text articles being
eligible for inclusion in our review. We then excluded 17
articles based on the eligibility criteria, leaving 14 articles
that met all eligibility criteria for the systematic review.
Study Characteristics
QoL data were included for 1556 patients who had
undergone CRS ? HIPEC for peritoneal metastases due to
a range of primary tumors (Table 1).22,27–39 There were 12
prospective and 2 retrospective studies; 8 were conducted
in North America, 5 in Europe, and 1 in Asia. The studies
used 12 different types of validated questionnaire to assess
QoL after CRS ? HIPEC. Most common among these
were the Functional Assessment of Cancer Therapy
(FACT), the European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30, the Medical
Outcomes Study Health Survey Short Form (SF-36), and
the Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (Supplementary Table 2). Most prospective
studies conducted measurements at baseline and at 3, 6,
and 12 months after surgery. Characteristics of the
CRS ? HIPEC procedures performed in the different
studies can be found in Supplementary Table 3.
Excluding three studies,29,31,33 dropout rates were
9–51% at 6 months and 10–75% at 12 months
(Fig. 2)22,28,30–32,34–38 and were mostly explained by the
high mortality of 3–18%.22,28,30,34,36,37 Other reasons for
dropout were mentioned in one study, including that
patients were too sick (13%) or refused (6%) to participate
further, but with no reason recorded in many cases
(32%).30
Quality and Risk of Bias Assessment
To evaluate the quality of the included articles, we
performed a risk of bias assessment using the MINORS
criteria, the results of which are summarized in Supple-
mentary Table 4.25 All of the included studies were
observational, and none reached the global ideal scores.
The mean MINORS score was 9.83 (range 6–11) for the
noncomparative studies and 14.50 (range 14–15) for the
comparative studies. None of the included studies reached
the maximum scores because their aims were unclear or
because we could not determine whether prospective data
collection was performed according to a previously
reported protocol. However, 12 studies reported their
endpoints in an adequate manner. Loss to follow-up was
not reported in 3 studies (16%), but it was reported in the
other 11 studies (84%), where it exceeded the 5% limit
applied by the MINORS criteria. Note that loss to follow-
up[ 5% is common in QoL research. We therefore eval-
uated the quality of the studies as mediocre. The ICC
between the two reviewers, 0.95, was almost perfect.
Development of QoL During Follow-Up
The general picture after CRS ? HIPEC was for QoL to
decrease over the first 3 months, to begin to recover by
6 months, and to reach or exceed the baseline measure-
ments by 12 months (Fig. 3).22,27–31,34–38 This change in
QoL was also evident in the different QoL domains,
including physical health,22,27–38 emotional health,22,27–38
social health,22,27–34,36–38 functional health,22,27–35,37,38 and
cognitive health (Fig. 4).22,27,29,37 Symptoms that most
frequently arose or worsened within the first 6 months after
surgery were fatigue, dyspnea, insomnia, and diarrhea.
However, all symptoms except for diarrhea had improved
by 12 months after surgery (Table 2).22,27,28,30,34,35,37
Quality of Life After CRS ? HIPEC
Several studies described an increased level of pain
3 months after CRS ? HIPEC compared with baseline
levels. Thereafter pain levels decreased, reaching levels
lower than baseline at 6 months.28,30,34,35,37
Determinants of QoL
A variety of patient-, tumor-, and treatment-related
factors were evaluated to determine their impact on QoL
after CRS ? HIPEC (Table 3).22,27,29, 30,32,33, 35,36,38,39
Factors that negatively influenced QoL after CRS ?
HIPEC were higher age,32,33 female sex,27,32 prolonged
operation time,22,36 high completeness of cytoreduction
(CC) score,22,32,33, 36 treatment with adjuvant chemother-
apy,22,33 postoperative complications,29,38 presence of a
stoma,22,32,36 and disease recurrence within 12 months.22,36
A high Peritoneal Cancer Index (PCI) before CRS ?
HIPEC also influenced the QoL negatively,22,32,36 although
one study found a statistically nonsignificant negative
effect of the PCI on QoL in the first 6 months and a pos-
itive effect in the subsequent 6 months.27
When comparing studies by dropout rate, there was no
difference in overall QoL between the studies with high
([ 50%) and low (\ 50%) rates (Fig. 3). Results were




















•     Other language (n=2)
•     Did not include QoL
       measures (n=2)
•     No valid questionnaire
      (n=1)
•     Re-HIPEC (n=1)
•     SPIC (n=1)
•     PIC (n=3)
•     Cross-sectional (7)









FIG. 1 Flowchart of systematic review. HIPEC hyperthermic intraperitoneal chemotherapy, IPC intraperitoneal chemotherapy, QoL quality of
life, SPIC sequential perioperative intraperitoneal chemotherapy












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Quality of Life After CRS ? HIPEC
Drop-out 12 months after CRS+ HIPEC
CHIA 2016 DODSON 2016 HILL 2011 HINKLE 2017


























FIG. 2 Dropout rates. CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy
































































FIG. 3 Overall QoL. EORTC
QLQ-C30 European
Organisation for Research and
Treatment of Cancer Quality of
Life of Cancer Patients, FACT
Functional Assessment of
Cancer Therapy, GIQLI
Gastrointestinal Quality of Life
index, QoL quality of life
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DISCUSSION
This systematic review identified several factors that
negatively influence QoL after CRS ? HIPEC. These
factors are higher patient age, female sex, prolonged
operation time, extensive disease (higher PCI), more
residual disease after surgery (higher CC score), adjuvant
chemotherapy, postoperative complications, stoma place-
ment, and disease recurrence. It was striking that dropout
rates did not affect these results. Overall, most patients
experienced a significant decline in a broad range of QoL
domains during the first months after CRS ? HIPEC, but
generally recovered to preoperative levels by 6–12 months
after surgery.
The recovery process over the first year after CRS ?
HIPEC appears to be promising, but these results should be
interpreted with caution. Although we found no difference
in QoL among studies based on their dropout rates, we
must remember that our results only apply to patients who
remained in the studies. Only 4 of 14 studies reported QoL
data based on over half of their enrolled populations, and
patient deaths only explained a small amount of the drop-
outs. Most dropouts were for other reasons, such as patients
being too weak to continue with the study due to either
disease recurrence or significant symptomatology.30 Con-
sequently, QoL may be overestimated after
CRS ? HIPEC. However, only one study reported on the
reasons for dropout, so it is difficult to evaluate the possible
overestimation of QoL.
Another relevant issue was that the included studies
were of mediocre quality based on the MINORS criteria.
This included having small sample sizes (only five studies
included more than 80 patients) and heterogeneous patient
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FIG. 4 QoL by domain. EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients,
FACT Functional Assessment of Cancer Therapy, GIQLI Gastrointestinal Quality of Life index, QoL quality of life
Quality of Life After CRS ? HIPEC
of patients might be more determined by the different
tumor types and stages than the other factors. To evaluate
the impact of tumor type and stage on QoL, studies are
needed that stratify their data by tumor type and stage.
Moreover, some important factors that could have affected
QoL (e.g., patient characteristics, tumor characteristics,
HIPEC regimens, and postoperative morbidity) were only
analyzed in a few studies.22,31,33 It was also notable that
there had been no consideration as to whether some factors
were associated with each other.
A strength of the included studies was that they all used
standardized and validated questionnaires. However, the
results may fail to give a comprehensive view of the QoL
of patients after CRS ? HIPEC specifically, not least
because the applied questionnaires were not designed for
this purpose. Furthermore, the studies used different vali-
dated questionnaires to assess QoL and measured QoL at
differing times. In studies using in-depth semi structured
interviews to collect QoL data after CRS ? HIPEC,
physical symptoms were reported to persist in at least half
of the patients between 6 and 12 months after surgery.
These included chronic pain, diet restrictions, ongoing
gastrointestinal problems, and sleep difficulties.40 In other
cases, patients described crying spells, depression, and
stoma-related problems (e.g., social issues, negative effect
on intimate relationships, and constant reminder of dis-
ease),41 as well as uncertainty about the future or death.42
These symptoms and their impact on QoL can be missed
when using questionnaires that are not disease specific.
This may be rectified by developing a standardized and
validated questionnaire for use after CRS ? HIPEC.
Most included studies described that QoL domains
returned to baseline levels after CRS ? HIPEC. However,
it must be remembered that baseline QoL levels were
measured shortly before the operation, when patients might
have already been suffering from clinical symptoms of
their disease. Therefore, QoL may have been already lower
compared with the QoL before the onset of the disease, as
it has been reported in patients suffering from malignant
ascites before CRS ? HIPEC.35 Therefore, it is question-
able whether we should consider a return to baseline QoL a
sufficient metric. It has been shown that patients who
received CRS ? HIPEC and remained disease-free during
follow-up scored higher on overall health than patients who
developed untreatable recurrent or metastatic disease.43
After 1 year of follow-up, their QoL scores were also
reported as comparable to those of patients with cancer
who undergo surgery without HIPEC and to those of
patients who are disease free and functioning well.44,45
However, QoL scores are still reported to be lower than in
the general population.46 Clinicians and patients must
therefore consider that QoL may remain lower than before
the disease first developed. When making clinical deci-
sions, we advocate that practitioners consider the patient’s
expectations and their perspectives regarding QoL, life
goals, and other influential factors.
In conclusion, this review shows that QoL after
CRS ? HIPEC tends to be negatively affected by certain
patient characteristics, procedure-specific outcomes, and
postoperative disease. Notably, study dropout rates did not
affect these factors. Although most patients experience a
significant decline in a broad range of QoL domains during
the first few months after CRS ? HIPEC, they generally
recover to preoperative levels by 6–12 months. Future
research should now focus on study designs that can
describe the profound experiences of patients who have
undergone CRS ? HIPEC. Given that factors affecting
QoL can only be partially influenced, it is essential that
patients receive detailed and honest counseling about these
outcomes before CRS ? HIPEC.
TABLE 2 Overall trend of impact of CRS with HIPEC on different
symptoms short- and long-term
Short-term symptom Long-term symptom












CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal
chemotherapy
*Nonsignificant increase of symptom compared with prior assessment
(e.g., preoperative assessment or within 6 months after surgery
assessment)
**Significant increase of symptom compared with preoperative
assessment (p\ 0.005)
***Nonsignificant decrease of symptom compared with prior
assessment
Significant decrease of symptom compared with prior assessment
Increase of symptom above preoperative assessment
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